Early passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior

BACKGROUND: Bone marrow-derived allogeneic mesenchymal stem cells (MSCs) from young healthy donors are immunoprivileged and their clinical application for regenerative medicine is under evaluation. However, data from preclinical and initial clinical trials indicate that allogeneic MSCs after transpl...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Stem Cell Res Ther
Päätekijät: Sareen, Niketa, Sequiera, Glen Lester, Chaudhary, Rakesh, Abu-El-Rub, Ejlal, Chowdhury, Subir Roy, Sharma, Vikram, Surendran, Arun, Moudgil, Meenal, Fernyhough, Paul, Ravandi, Amir, Dhingra, Sanjiv
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2018
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5930635/
https://ncbi.nlm.nih.gov/pubmed/29720263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13287-018-0867-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia